Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells 13,548 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 13,548 shares of Liquidia stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $507,101.64. Following the sale, the insider owned 184,174 shares in the company, valued at $6,893,632.82. This trade represents a 6.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jason Adair also recently made the following trade(s):

• On Monday, December 1st, Jason Adair sold 693 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total value of $22,307.67.
• On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The shares were sold at an average price of $30.03, for a total transaction of $1,070,749.68.
• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The shares were sold at an average price of $22.93, for a total value of $15,867.56.

Liquidia Price Performance

Liquidia stock traded up $1.49 during midday trading on Tuesday, reaching $38.09. The company’s stock had a trading volume of 2,055,159 shares, compared to its average volume of 2,814,845. The stock’s 50 day simple moving average is $31.94 and its 200 day simple moving average is $25.40. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The firm has a market capitalization of $3.31 billion, a PE ratio of -26.45, a P/E/G ratio of 1.19 and a beta of 0.48. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $39.29.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. The business’s revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, equities research analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Jefferies Financial Group lifted their price target on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright lifted their target price on Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Needham & Company LLC boosted their price target on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Raymond James Financial restated a “strong-buy” rating and issued a $47.00 price objective on shares of Liquidia in a report on Tuesday, November 4th. Finally, BTIG Research restated a “buy” rating and issued a $49.00 price target on shares of Liquidia in a report on Friday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC bought a new position in Liquidia during the 2nd quarter worth approximately $25,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia during the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC bought a new position in Liquidia during the third quarter worth $34,000. Steward Partners Investment Advisory LLC boosted its holdings in Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after purchasing an additional 4,927 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).